{
    "clinical_study": {
        "@rank": "80798", 
        "arm_group": [
            {
                "arm_group_label": "KAD-1229", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as\n      combination therapy with insulin in patients with type 2 Diabetes Mellitus who show\n      inadequate glycemic control with diet, and insulin monotherapy, or insulin and oral\n      hypoglycemic agent."
        }, 
        "brief_title": "Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus", 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who has been receiving dietary therapy and a stable dose and regimen of\n             insulin over 8 weeks before at the time of an observation term start\n\n          -  Patients whose HbA1c at the time of an observation term start is 7.5% or more and\n             less than 10.0%\n\n        Exclusion Criteria:\n\n          -  Type 1 Diabetes Mellitus\n\n          -  Patients with serious diabetic complications and other serious complications"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "firstreceived_date": "May 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154347", 
            "org_study_id": "KAD6401"
        }, 
        "intervention": [
            {
                "arm_group_label": "KAD-1229", 
                "intervention_name": "KAD-1229", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "KAD-1229", 
                    "Placebo"
                ], 
                "intervention_name": "Insulin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mitiglinide"
        }, 
        "keyword": [
            "Type 2 Diabetes Mellitus", 
            "HbA1c"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo and Other Japanese City", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "overall_contact": {
            "email": "rinsyousiken@pharm.kissei.co.jp", 
            "last_name": "Kissei Pharmaceutical Co., Ltd"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in HbA1c", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154347"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidences of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "source": "Kissei Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kissei Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}